Michael G. Muto, MD

Associate Professor, Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School

Director, Gynecologic Oncology Fellowship Program, Brigham And Women's Hospital

Contact Info

Michael Muto
Brigham And Women's Hospital
75 Francis Street
Boston, MA, 02115
Mailstop: Dept of Ob/Gyn, ASB1-3
Phone: 617-732-8840
Fax: 617-738-5124
mmuto@partners.org

Assistant

Not Available.

DF/HCC Program Affiliation

Gynecologic Cancers
Cancer Genetics

Research Abstract

Dr. Muto has a special research interest in ovarian cancer occurring in women with a genetic predisposition to the disease. He is Co-Director of the Familial Ovarian Cancer Center in the Cancer Risk and Prevention Service at the Dana-Farber Cancer Institute. In this capacity, he is involved in the clinical management of women with BRCA-1 and BRCA-2 mutations. He is interested in chemoprevention, the efficacy of ultrasound, and CA-125 in early detection and in the role of prophylactic surgery in the prevention of ovarian cancer in these high risk women. His clinical activity supports molecular biologic studies in the etiology of papillary serous carcinoma of the peritoneum, a disease which may occur following prophylactic surgery and which has an impact upon the effectiveness of the operation.

Publications

View All Publications

Advanced search
DF/HCC Directory Login Update Member Profile Change Account Settings Applying for Membership Benefits Requirements Responsibilities	Michael G. Muto, MD Associate Professor, Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School Director, Gynecologic Oncology Fellowship Program, Brigham And Women's Hospital Contact Info Michael Muto Brigham And Women's Hospital 75 Francis Street Boston, MA, 02115 Mailstop: Dept of Ob/Gyn, ASB1-3 Phone: 617-732-8840 Fax: 617-738-5124 mmuto@partners.org Assistant Not Available. DF/HCC Program Affiliation Gynecologic Cancers Cancer Genetics Research Abstract Dr. Muto has a special research interest in ovarian cancer occurring in women with a genetic predisposition to the disease. He is Co-Director of the Familial Ovarian Cancer Center in the Cancer Risk and Prevention Service at the Dana-Farber Cancer Institute. In this capacity, he is involved in the clinical management of women with BRCA-1 and BRCA-2 mutations. He is interested in chemoprevention, the efficacy of ultrasound, and CA-125 in early detection and in the role of prophylactic surgery in the prevention of ovarian cancer in these high risk women. His clinical activity supports molecular biologic studies in the etiology of papillary serous carcinoma of the peritoneum, a disease which may occur following prophylactic surgery and which has an impact upon the effectiveness of the operation. Publications View All Publications
Site Map Site Feedback Web Privacy Policy